ArticleIEEE transactions on medical imaging2011
A statistical modeling approach to the analysis of spatial patterns of FDG-PET uptake in human sarcoma.
Article in IEEE transactions on medical imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Quantification of heterogeneity as a biomarker in tumor imaging: a systematic review.PloS one · 2014Pooled it
- Alveolar Rhabdomyosarcoma of Nasopharynx and Paranasal Sinuses in Children Diagnosis and Treatment-Review of the Literature and Case Report.Medicina (Kaunas, Lithuania) · 2025Review
- Spatially coherent modeling of 3D FDG-PET data for assessment of intratumoral heterogeneity and uptake gradients.Journal of medical imaging (Bellingham, Wash.) · 2022Article
- Assessment of different quantification metrics of [Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Positron emission tomography-based assessment of metabolic gradient and other prognostic features in sarcoma.Journal of medical imaging (Bellingham, Wash.) · 2018Article
- Towards enhanced PET quantification in clinical oncology.The British journal of radiology · 2018Review
- Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans.Statistics in medicine · 2017Article
- Article
- Rhabdomyosarcoma in adults: new perspectives on therapy.Current treatment options in oncology · 2015Review
- Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology.Nuclear medicine and molecular imaging · 2014Review
- FDG uptake heterogeneity in FIGO IIb cervical carcinoma does not predict pelvic lymph node involvement.Radiation oncology (London, England) · 2013Article
- Tumor quantification in clinical positron emission tomography.Theranostics · 2013Review
- Robustness of intratumour ¹⁸F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma.European journal of nuclear medicine and molecular imaging · 2013Article
- Role of Textural Analysis of PretreatmentIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Clinical experience with positron emission tomography (PET) scanning of sarcoma, using fluorodeoxyglucose (FDG), has established spatial heterogeneity in the standardized uptake values within the tumor mass as a key prognostic indicator of patient survival. But it may be that a more detailed quantitation of the tumor FDG uptake pattern could provide additional insights into risk. The present work develops a statistical model for this purpose. The approach is based on a tubular representation of the tumor mass with a simplified radial analysis of uptake, transverse to the tubular axis. The technique provides novel ways of characterizing the overall profile of the tumor, including the introduction of an approach for the measurement of its phase of development. The phase measure can distinguish between early phase tumors, in which the uptake is highest at the core, and later stage masses, in which there can often be central voids in FDG uptake. Biologically, these voids arise from necrosis and fluid, fat or cartilage accumulations. The tumor profiling technique is implemented using open-source software tools and illustrations are provided with clinically representative scans. A series of FDG-PET studies from 185 patients is used to formally evaluate the prognostic benefit. Significant improvements in the prediction of patient survival and progression are obtained from the tumor profiling analysis. After adjustment for other factors including heterogeneity, a typical one standard deviation increase in phase (as determined by the analysis) is associated with close to 20% more risk of progression or death. The work confirms that more detailed quantitative assessments of the spatial pattern of PET imaging data of tumor masses, beyond the maximum FDG uptake (SUV(max)) and previously considered measures of heterogeneity, provide improved prognostic information for potential input to treatment decisions for future patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.